| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Fibrinogen-Binding Peptide targets fibrinogen, a glycoprotein that plays a central role in hemostasis and thrombosis. Fibrinogen is the final protein in the coagulation cascade and is converted to fibrin by thrombin, forming the structural matrix of blood clots. The peptide is designed as a mimic of the vitronectin binding site on the fibrinogen receptor (integrin alphaIIbbeta3, also known as GPIIb/IIIa). By binding to fibrinogen, the peptide inhibits the adhesion of platelets to fibrinogen and prevents platelet aggregation. The peptide also inhibits platelet adhesion to vitronectin. This mechanism makes the peptide a valuable tool for studying platelet function and thrombosis.
|
|---|---|
| ln Vitro |
Fibrinogen-Binding Peptide demonstrates potent in vitro activity in inhibiting platelet function. The peptide binds to fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation. It also inhibits the adhesion of platelets to vitronectin. The peptide's activity is concentration-dependent, with effects observed at appropriate concentrations. As a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor, the peptide was designed through the anticomplementarity hypothesis. Its in vitro activity has been characterized in platelet adhesion and aggregation assays. The peptide's specificity for fibrinogen and the fibrinogen receptor makes it a valuable research tool.
|
| ln Vivo |
In vivo activity of Fibrinogen-Binding Peptide has been less extensively characterized compared to its in vitro activity. As a peptide that inhibits platelet adhesion and aggregation, the compound would be expected to have antithrombotic effects in vivo. The peptide's ability to bind fibrinogen and inhibit platelet aggregation suggests potential for studying thrombosis and hemostasis. However, comprehensive in vivo efficacy studies in animal models have not been extensively reported. The peptide is primarily used as a research tool for in vitro studies of platelet function and fibrinogen receptor biology. Further research is needed to determine whether the peptide's in vitro activities translate to in vivo efficacy.
|
| Enzyme Assay |
In vitro receptor binding assays for Fibrinogen-Binding Peptide involve measuring binding affinity to fibrinogen. Fibrinogen-coated plates or fibrinogen immobilized on beads are incubated with labeled peptide or labeled fibrinogen receptor (integrin alphaIIbbeta3) and varying concentrations of the test peptide. Bound and free ligand are separated, and binding affinity is calculated from competition curves using non-linear regression analysis. Alternatively, surface plasmon resonance (SPR) can be used to measure real-time binding kinetics between the peptide and fibrinogen. Platelet aggregation assays are performed using platelet-rich plasma (PRP) or washed platelets stimulated with agonists such as ADP, collagen, or thrombin. The peptide's ability to inhibit platelet aggregation is measured by light transmission aggregometry. Each concentration is typically tested in duplicate or triplicate.
|
| Cell Assay |
In vitro cellular assays for Fibrinogen-Binding Peptide are performed using platelets to assess inhibition of adhesion and aggregation. Platelet-rich plasma (PRP) or washed platelets are incubated with varying concentrations of the peptide. Platelet aggregation is induced by the addition of agonists such as ADP, collagen, or thrombin, and aggregation is measured using light transmission aggregometry. For adhesion assays, platelets are allowed to adhere to fibrinogen-coated surfaces in the presence or absence of the peptide, and adherent platelets are quantified by colorimetric or fluorescence-based methods. The peptide's ability to inhibit platelet adhesion to vitronectin can be assessed using vitronectin-coated surfaces. Cytotoxicity is assessed in parallel using standard viability assays to ensure that observed effects are not due to platelet damage. IC50 values for inhibition of aggregation or adhesion are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for Fibrinogen-Binding Peptide have not been extensively reported in the public domain. As a peptide that inhibits platelet adhesion and aggregation, the compound could potentially be evaluated in animal models of thrombosis, such as the ferric chloride-induced arterial thrombosis model or the pulmonary embolism model. In such studies, the peptide would be administered via intravenous injection, and endpoints would include thrombus formation, bleeding time, and survival. Pharmacokinetic studies would assess peptide concentrations in plasma. However, comprehensive in vivo efficacy and pharmacokinetic studies have not been widely published. The peptide is primarily used as a research tool for in vitro studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Fibrinogen-Binding Peptide have not been extensively characterized in the public domain. The peptide has a molecular formula of C25H39N7O8 and a molecular weight of 565.62 g/mol. Its IUPAC name is (S)-4-amino-5-(((S)-1-(((2S,3S)-1-((S)-2-(((S)-1-carboxyethyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxopentan-2-yl)amino)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid. As a pentapeptide, the compound is susceptible to proteolytic degradation and would have a short half-life in circulation. The peptide is typically administered by injection due to poor oral bioavailability. Comprehensive pharmacokinetic parameters have not been reported.
|
| Toxicity/Toxicokinetics |
Fibrinogen-Binding Peptide is intended for laboratory research use only and has not undergone comprehensive toxicology testing. As a peptide designed to inhibit platelet function, the compound would be expected to have antithrombotic effects and could potentially affect hemostasis. Standard in vitro cytotoxicity assays in cell lines are typically performed alongside efficacy studies to rule out nonspecific toxicity. In vivo, animals would be monitored for signs of toxicity including bleeding, body weight changes, and clinical observations if the compound were to be evaluated in animal studies. Comprehensive toxicological characterization has not been reported. The peptide is not approved for human use and is strictly intended for research purposes.
|
| Additional Infomation |
Fibrinogen-Binding Peptide is a synthetic pentapeptide (EHIPA) designed using the anticomplementarity hypothesis as a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. It binds fibrinogen and inhibits platelet adhesion to fibrinogen and platelet aggregation. It also inhibits platelet adhesion to vitronectin. The compound has a molecular formula of C25H39N7O8 and a molecular weight of 565.62 g/mol. Fibrinogen-Binding Peptide has not entered clinical trials and is available for research purposes only.
|
| Molecular Formula |
C25H39N7O8
|
|---|---|
| Molecular Weight |
565.61926
|
| Exact Mass |
565.286
|
| CAS # |
137235-80-4
|
| Related CAS # |
Fibrinogen-Binding Peptide TFA
|
| PubChem CID |
5487438
|
| Appearance |
White to off-white solid powder
|
| Density |
1.343 g/cm3
|
| Boiling Point |
1067.8ºC at 760 mmHg
|
| Flash Point |
599.6ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.577
|
| LogP |
0.551
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
40
|
| Complexity |
948
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC[C@@H]([C@H](NC([C@@H](NC([C@@H](N)CCC(O)=O)=O)CC1=CN=CN1)=O)C(N2CCC[C@H]2C(N[C@H](C(O)=O)C)=O)=O)C
|
| InChi Key |
VWJLJHZPMZGDDV-HOCDWTQPSA-N
|
| InChi Code |
InChI=1S/C25H39N7O8/c1-4-13(2)20(24(38)32-9-5-6-18(32)23(37)29-14(3)25(39)40)31-22(36)17(10-15-11-27-12-28-15)30-21(35)16(26)7-8-19(33)34/h11-14,16-18,20H,4-10,26H2,1-3H3,(H,27,28)(H,29,37)(H,30,35)(H,31,36)(H,33,34)(H,39,40)/t13-,14-,16-,17-,18-,20-/m0/s1
|
| Chemical Name |
(4S)-4-amino-5-[[(2S)-1-[[(2S,3S)-1-[(2S)-2-[[(1S)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~147.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7680 mL | 8.8399 mL | 17.6797 mL | |
| 5 mM | 0.3536 mL | 1.7680 mL | 3.5359 mL | |
| 10 mM | 0.1768 mL | 0.8840 mL | 1.7680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
